Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 177,704 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16. Following the completion of the transaction, the chief operating officer now directly owns 740,976 shares in the company, valued at $8,550,863.04. This trade represents a 19.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Eric Venker also recently made the following trade(s):

• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00.

Roivant Sciences Stock Up 2.1 %

ROIV opened at $12.08 on Friday. The business has a 50 day moving average price of $11.92 and a two-hundred day moving average price of $11.56. Roivant Sciences Ltd. has a 52 week low of $9.69 and a 52 week high of $13.06. The company has a market cap of $8.79 billion, a PE ratio of 2.14 and a beta of 1.25.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Bank of America boosted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, November 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently modified their holdings of ROIV. JPMorgan Chase & Co. grew its position in Roivant Sciences by 4.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 822,582 shares of the company’s stock valued at $9,493,000 after buying an additional 34,453 shares during the last quarter. Retirement Systems of Alabama boosted its holdings in shares of Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares in the last quarter. Tyro Capital Management LLC boosted its holdings in shares of Roivant Sciences by 0.6% in the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company’s stock valued at $20,252,000 after acquiring an additional 10,649 shares in the last quarter. Te Ahumairangi Investment Management Ltd increased its stake in shares of Roivant Sciences by 19.9% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company’s stock worth $2,313,000 after acquiring an additional 33,467 shares during the period. Finally, Virtu Financial LLC purchased a new position in Roivant Sciences during the third quarter worth about $207,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.